Restenosis after PCI. Part 1: pathophysiology and risk factors
暂无分享,去创建一个
J. Jukema | J. Verschuren | T. Ahmed | P. Quax | P. Quax | Paul H.A. Quax
[1] M. Uslenghi,et al. The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.
[2] W. Siegenthaler,et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.
[3] L. Bentivoglio. Percutaneous transluminal coronary angioplasty. , 1979, Annals of internal medicine.
[4] R E Vlietstra,et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.
[5] F Joffre,et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.
[6] A. Hassid,et al. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.
[7] M. Savage,et al. Restenosis after coronary angioplasty: A multilvariate statistical model to relate lesion and procedure variables to restenosis☆ , 1991 .
[8] T. Ogihara,et al. A potent genetic risk factor for restenosis , 1993, Nature Genetics.
[9] E. Topol,et al. Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomy. , 1993, The American journal of cardiology.
[10] Charles L. Brown,et al. Can restenosis after coronary angioplasty be predicted from clinical variables? , 1993, Journal of the American College of Cardiology.
[11] P. Teirstein,et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.
[12] R. Califf. Restenosis: the cost to society. , 1995, American heart journal.
[13] J. Pollock,et al. Restenosis is associated with decreased coronary artery nitric oxide synthase. , 1997, International journal of cardiology.
[14] M. Hadamitzky,et al. Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.
[15] P. Amouyel,et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. , 1997, Circulation.
[16] D. Holmes,et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. , 1997, The New England journal of medicine.
[17] A. Kastrati,et al. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions. , 1998, Circulation.
[18] M. Leon,et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.
[19] M. Leon,et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.
[20] M. Hadamitzky,et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.
[21] G. Stone,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.
[22] C. Di Mario,et al. Stented segment length as an independent predictor of restenosis. , 1999, Journal of the American College of Cardiology.
[23] A. Kastrati,et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. , 1999, Circulation.
[24] J. Pell. Does smoking cessation reduce the risk of restenosis following coronary angioplasty? , 2000, Heart.
[25] Christian W Hamm,et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis , 2000, The Lancet.
[26] J. Danesh,et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.
[27] M. Lamfers,et al. Adenoviral Expression of a Urokinase Receptor–Targeted Protease Inhibitor Inhibits Neointima Formation in Murine and Human Blood Vessels , 2001, Circulation.
[28] J. Popma,et al. Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention: Another Smoker’s Paradox? , 2001, Circulation.
[29] M. Lamfers,et al. In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI , 2001, Gene Therapy.
[30] J. Jukema,et al. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. , 2001, European heart journal.
[31] D. Baim,et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. , 2002, Journal of the American College of Cardiology.
[32] A. Zwinderman,et al. A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. , 2002, American heart journal.
[33] R. Erbel,et al. Evaluation of metal allergies in patients with coronary stents , 2002, Contact dermatitis.
[34] U. Ikeda,et al. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. , 2002, Atherosclerosis.
[35] Gary S. Mintz,et al. Intravascular Ultrasound Guidance Improves Angiographic and Clinical Outcome of Stent Implantation for Long Coronary Artery Stenoses: Final Results of a Randomized Comparison With Angiographic Guidance (TULIP Study) , 2003, Circulation.
[36] D. Sedding,et al. Mechanosensitive p27Kip1 Regulation and Cell Cycle Entry in Vascular Smooth Muscle Cells , 2003, Circulation.
[37] Rossella Fattori,et al. Drug-eluting stents in vascular intervention , 2003, The Lancet.
[38] A. Kastrati,et al. Tumor necrosis factor-α, lymphotoxin-α, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting , 2003 .
[39] A. Kastrati,et al. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. , 2003, Cytokine.
[40] J. Brophy,et al. Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis , 2003, Annals of Internal Medicine.
[41] Lawrence Joseph,et al. Evidence for Use of Coronary Stents , 2003 .
[42] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[43] Robyn L McClelland,et al. Clinical and Angiographic Predictors of Restenosis After Percutaneous Coronary Intervention: Insights From the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) Trial , 2004, Circulation.
[44] B. Zinman,et al. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. , 2004, Diabetes care.
[45] D. Baim,et al. Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials , 2004, Circulation.
[46] J. Jukema,et al. Genetic predictive factors in restenosis. , 2004, Pathologie-biologie.
[47] Michael S. Lee,et al. Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation–fibrinolysis system , 2004, The Journal of pathology.
[48] A. Zwinderman,et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. , 2004, European heart journal.
[49] A. Mangi,et al. Enhanced Inhibition of Neointimal Hyperplasia by Genetically Engineered Endothelial Progenitor Cells , 2004, Circulation.
[50] T. Walley,et al. Angioplasty and stents in coronary artery disease: a systematic review and meta‐analysis , 2004, Scandinavian cardiovascular journal : SCJ.
[51] I. Iakovou,et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.
[52] V. Fuster,et al. Looking for the culprit of coronary in‐stent restenosis: debatable role for the fibrinolytic system? , 2005, Journal of thrombosis and haemostasis : JTH.
[53] Y. Jang,et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. , 2005, The American journal of cardiology.
[54] P. Serruys,et al. Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial , 2005, Circulation.
[55] S. Anker,et al. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis , 2005, Journal of Molecular Medicine.
[56] A. Zwinderman,et al. Tumor necrosis factor- plays an important role in restenosis development , 2005 .
[57] A. Zwinderman,et al. Tumor necrosis factor-alpha plays an important role in restenosis development. , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] A. Zwinderman,et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. , 2005, Diabetes care.
[59] K. Huber,et al. Predictive value of plasma plasminogen activator inhibitor‐1 for coronary restenosis: dependence on stent implantation and antithrombotic medication , 2005, Journal of thrombosis and haemostasis : JTH.
[60] Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. , 2005, International journal of molecular medicine.
[61] A. Zwinderman,et al. Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions , 2005, Circulation.
[62] A. Kastrati,et al. Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents , 2006, Circulation.
[63] Matthew H Samore,et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.
[64] U. Dietz,et al. Shortening the stent length reduces restenosis with bare metal stents: matched pair comparison of short stenting and conventional stenting , 2005, Heart.
[65] 岩澤 秀明,et al. Asymmetric Dimethylarginine , 2006, Definitions.
[66] B. Binder. Thrombin is bad, accepted; but is smoking good to prevent restenosis? , 2006, Journal of thrombosis and haemostasis : JTH.
[67] A. Zwinderman,et al. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1 , 2006, Pharmacogenetics and genomics.
[68] G. Montalescot,et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials , 2005, Heart.
[69] Junbo Ge,et al. Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis. , 2006, International journal of cardiology.
[70] P. Quax,et al. Inhibition of Complement Component C3 Reduces Vein Graft Atherosclerosis in Apolipoprotein E3–Leiden Transgenic Mice , 2006, Circulation.
[71] A. Zwinderman,et al. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention , 2007, Genes and Immunity.
[72] A. Feinberg,et al. Genetics and epigenetics--nature's pen-and-pencil set. , 2007, The New England journal of medicine.
[73] U. Galderisi,et al. Pathophysiology of stem cells in restenosis. , 2007, Histology and histopathology.
[74] Plasminogen activator inhibitor-1 and restenosis. , 2007, Current drug targets.
[75] K. Kent,et al. Correlates of clinical restenosis following intracoronary implantation of drug-eluting stents. , 2007, The American journal of cardiology.
[76] T. Murohara,et al. Genetic risk for restenosis after coronary stenting. , 2007, Atherosclerosis.
[77] T. Lagerweij,et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. , 2007, Atherosclerosis.
[78] Stéphane G Carlier,et al. Intravascular ultrasound assessment of drug-eluting stent expansion. , 2007, American heart journal.
[79] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[80] A. Zwinderman,et al. The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions , 2007, Thrombosis and Haemostasis.
[81] F. Burzotta,et al. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. , 2008, Cardiovascular revascularization medicine : including molecular interventions.
[82] Frederic S. Resnic,et al. Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts , 2008, Circulation.
[83] Timothy O'Brien,et al. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[84] G. Maurer,et al. Plasminogen activator inhibitor‐1 predicts coronary in‐stent restenosis of drug‐eluting stents , 2008, Journal of thrombosis and haemostasis : JTH.
[85] A. Zwinderman,et al. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions , 2008, Human mutation.
[86] H. Putter,et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. , 2008, Journal of the American College of Cardiology.
[87] J. Jukema,et al. Epigenetic histone acetylation modifiers in vascular remodelling – new targets for therapy in cardiovascular disease , 2008, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.
[88] N. Weissman,et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. , 2008, European heart journal.
[89] F. Schmidt. Meta-Analysis , 2008 .
[90] A. Itai,et al. The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. , 2008, Expert opinion on therapeutic targets.
[91] M. Kimura,et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[92] B. Brott,et al. Stainless Steel Ions Stimulate Increased Thrombospondin-1-Dependent TGF-Beta Activation by Vascular Smooth Muscle Cells: Implications for In-Stent Restenosis , 2009, Journal of Vascular Research.
[93] E. Erdoğan,et al. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine , 2010, Heart and Vessels.
[94] A. V. Rij,et al. Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis. , 2009, Atherosclerosis.
[95] D. Wei,et al. Important role of TNF-alpha in inhibitory effects of Radix Sophorae Flavescentis extract on vascular restenosis in a rat carotid model of balloon dilatation injury. , 2009, Planta medica.
[96] P. Kala,et al. Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting. , 2009, Vnitrni lekarstvi.
[97] P. Teirstein,et al. A Randomized Controlled Trial of Angiography Versus Intravascular Ultrasound-Directed Bare-Metal Coronary Stent Placement (The AVID Trial) , 2009, Circulation. Cardiovascular interventions.
[98] A. Zwinderman,et al. Metabolic Background Determines the Importance of NOS3 Polymorphisms in Restenosis after Percutaneous Coronary Intervention: A Study in Patients with and without the Metabolic Syndrome , 2006, Disease markers.
[99] F. Baas,et al. p27kip1–838C>A Single Nucleotide Polymorphism Is Associated With Restenosis Risk After Coronary Stenting and Modulates p27kip1 Promoter Activity , 2009, Circulation.
[100] D. Lawrence,et al. Recombinant Plasminogen Activator Inhibitor-1 Inhibits Intimal Hyperplasia , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[101] Taro Saito,et al. Metal allergic reaction in chronic refractory in-stent restenosis. , 2009, Cardiovascular revascularization medicine : including molecular interventions.
[102] M. Pencina,et al. Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry , 2010, Circulation. Cardiovascular interventions.
[103] M. Amiji,et al. Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis , 2010, Biomedical engineering online.
[104] J. Jukema,et al. A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. , 2010, Cardiovascular research.
[105] P. Serruys,et al. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardi , 2010, JACC. Cardiovascular interventions.
[106] G. Lemesle,et al. Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[107] A. Uitterlinden,et al. Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention , 2010, Expert opinion on therapeutic targets.
[108] V. Pasceri,et al. Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: a prospective study. , 2010, JACC. Cardiovascular interventions.
[109] P. Serruys,et al. Coronary stents: current status. , 2010, Journal of the American College of Cardiology.
[110] G. Maurer,et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. , 2010, Atherosclerosis.
[111] M. Klomp,et al. Understanding the role of endothelial progenitor cells in cardiovascular disease, coronary artery lesion progression, and in-stent restenosis. , 2010, JACC. Cardiovascular interventions.
[112] P. de Knijff,et al. Matrix Metalloproteinases 2 and 3 Gene Polymorphisms and the Risk of Target Vessel Revascularization after Percutaneous Coronary Intervention: Is There Still Room for Determining Genetic Variation of MMPs for Assessment of an Increased Risk of Restenosis? , 2011, Disease markers.
[113] Y. Dundar,et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. , 2015, The Cochrane database of systematic reviews.
[114] A. Yeung,et al. Impact of C-reactive protein on in-stent restenosis: a meta-analysis. , 2010, Texas Heart Institute journal.
[115] Gary S Mintz,et al. In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.
[116] E. Edelman,et al. Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting , 2010, Reviews in Endocrine and Metabolic Disorders.
[117] R. Weiss,et al. Meta-analysis of incidence, clinical characteristics and implications of stent fracture. , 2010, The American journal of cardiology.
[118] G. Niccoli,et al. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. , 2010, Journal of the American College of Cardiology.
[119] J. Veselka,et al. CORONARY ARTERY DISEASE Original Studies Long-Term Health Outcome and Mortality Evaluation After Invasive Coronary Treatment Using Drug Eluting Stents with or without the IVUS Guidance. Randomized Control Trial. HOME DES IVUS , 2010 .
[120] G. Maurer,et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. , 2010, JACC. Cardiovascular interventions.
[121] Y. Hayashi,et al. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). , 2010, The American journal of cardiology.
[122] M. Leon,et al. Sex‐specific outcomes following revascularization with zotarolimus‐eluting stents: Comparison of angiographic and late‐term clinical results , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[123] T. Akasaka,et al. Serial angiographic findings and prognosis of stent fracture site without early restenosis after sirolimus-eluting stent implantation. , 2010, American heart journal.
[124] P. Serruys,et al. Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two‐year angiographic and three‐year clinical results from the SPIRIT II study , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[125] A. Zwinderman,et al. Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies , 2010, Heart.
[126] S. Brener,et al. The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials. , 2011, Atherosclerosis.
[127] S. Fichtlscherer,et al. A prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion (REGENT I extension). , 2011, Human gene therapy.
[128] G. Campo,et al. Long-term outcomes with cobalt-chromium bare-metal vs. drug-eluting stents: the REgistro regionale AngiopLastiche dell'Emilia-Romagna registry , 2011, Journal of cardiovascular medicine.
[129] Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation. , 2011, The Journal of invasive cardiology.
[130] G. Stone,et al. Meta-analysis of randomized studies comparing intravascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era. , 2011, The American journal of cardiology.
[131] Paul H. A. Quax,et al. Restenosis after PCI. Part 2: prevention and therapy , 2012, Nature Reviews Cardiology.
[132] V. Gudnason,et al. Hemostatic Factors and Risk of Coronary Heart Disease in General Populations: New Prospective Study and Updated Meta-Analyses , 2013, PloS one.
[133] H. Kwon,et al. Prospective Study , 2020, Encyclopedia of Behavioral Medicine.